These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 18204753)

  • 1. Successful treatment of a morbidly obese and growth-retarded adolescent with Williams-Beuren Syndrome by combining the medication of growth hormone and sibutramine.
    Bahadori B; Uitz E; Tonninger-Bahadori K; Moghadasian MH
    Singapore Med J; 2008 Jan; 49(1):e15-6. PubMed ID: 18204753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe symptomatic hyponatremia during sibutramine therapy: a case report.
    Esposito P; Rampino T; Gregorini M; Soccio G; Piotti G; Bedino G; Balenzano CT; Roscini E; Cosmai L; Portalupi V; Libetta C; Dal Canton A
    Am J Kidney Dis; 2008 Jul; 52(1):137-9. PubMed ID: 18487000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sibutramine as an adjuvant therapy in adolescents suffering from morbid obesity.
    Reisler G; Tauber T; Afriat R; Bortnik O; Goldman M
    Isr Med Assoc J; 2006 Jan; 8(1):30-2. PubMed ID: 16450748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of sibutramine therapy on occurrence of depression symptoms among obese patients.
    Slovacek L; Pavlik V; Slovackova B
    Nutr Metab Cardiovasc Dis; 2008 Oct; 18(8):e43-4. PubMed ID: 18676135
    [No Abstract]   [Full Text] [Related]  

  • 5. Does long-term use of sibutramine (Meridia) result in continued weight loss in short-term responders?
    Stevenson JH; Trojian T; Jackson EA
    J Fam Pract; 2001 Dec; 50(12):1084. PubMed ID: 11742615
    [No Abstract]   [Full Text] [Related]  

  • 6. Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene.
    Hsiao DJ; Wu LS; Huang SY; Lin E
    Pharmacogenet Genomics; 2009 Sep; 19(9):730-3. PubMed ID: 19687782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of isocaloric diets and sibutramine on food intake, body mass variation and serum TNF-alpha levels in rats.
    Trapali M; Liapi C; Perelas A; Perrea D; Stroubini T; Dontas I; Couvari E; Mavri M; Galanopoulou P
    Pharmacology; 2008; 82(1):15-21. PubMed ID: 18434760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Obesity: when does the internist recommend surgery?].
    Kunt T
    Zentralbl Chir; 2000; 125(3):293-7. PubMed ID: 10769452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sibutramine-induced anorexia: potent, dose-dependent and behaviourally-selective profile in male rats.
    Tallett AJ; Blundell JE; Rodgers RJ
    Behav Brain Res; 2009 Mar; 198(2):359-65. PubMed ID: 19061919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial.
    Maggioni AP; Caterson I; Coutinho W; Finer N; Gaal LV; Sharma AM; Torp-Pedersen C; Bacher P; Shepherd G; Sun R; James P;
    J Cardiovasc Pharmacol; 2008 Nov; 52(5):393-402. PubMed ID: 19033818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats.
    Roth JD; Trevaskis JL; Wilson J; Lei C; Athanacio J; Mack C; Kesty NC; Coffey T; Weyer C; Parkes DG
    Int J Obes (Lond); 2008 Aug; 32(8):1201-10. PubMed ID: 18560368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of sibutramine to assist obese women with weight loss can be successful in dietitian-led clinics: another tool in the dietitian's toolbox.
    Barratt R; Frost G; O'Boyle A; Millward J; Truby H
    J Hum Nutr Diet; 2008 Jun; 21(3):248-55. PubMed ID: 18477180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
    Sharma AM; Caterson ID; Coutinho W; Finer N; Van Gaal L; Maggioni AP; Torp-Pedersen C; Bacher HP; Shepherd GM; James WP;
    Diabetes Obes Metab; 2009 Mar; 11(3):239-50. PubMed ID: 18671798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of sibutramine on weight reduction and insulin resistance in women with polycystic ovary syndrome.
    Georgopoulos NA; Katsikis I; Florakis D; Panidis D; Kandarakis ED
    Fertil Steril; 2009 Jun; 91(6):e1. PubMed ID: 19362719
    [No Abstract]   [Full Text] [Related]  

  • 15. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
    Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of sibutramine-induced hyperprolactinemia.
    Soares Leaes CG; Pereira-Lima JF; da Costa Oliveira M
    Neuro Endocrinol Lett; 2011; 32(5):616-8. PubMed ID: 22167128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catatonia and psychosis associated with sibutramine: a case report and pathophysiologic correlation.
    Lee J; Teoh T; Lee TS
    J Psychosom Res; 2008 Jan; 64(1):107-9. PubMed ID: 18158006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sibutramine-associated psychosis (case report).
    Gazdag G; Szabó Z
    Neuropsychopharmacol Hung; 2008 May; 10(2):107-10. PubMed ID: 18959143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial.
    Andersson C; Weeke P; Fosbøl EL; Brendorp B; Køber L; Coutinho W; Sharma AM; Van Gaal L; Finer N; James WP; Caterson ID; Rode RA; Torp-Pedersen C; ;
    Metabolism; 2009 Aug; 58(8):1109-15. PubMed ID: 19454355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sympathetic-leptin relationship in obesity: effect of weight loss.
    Quilliot D; Böhme P; Zannad F; Ziegler O
    Metabolism; 2008 Apr; 57(4):555-62. PubMed ID: 18328360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.